SEC Form 4 · accession 0001193125-26-324447
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Zante
Officer — Chief Financial Officer
Period of report
Jul 28, 2026
Accepted (ET)
Jul 29, 2026 · 8:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF1,F2 | Jul 28, 2026 | A | 31,667 | $0.00 | A | 233,421 | D | |
| Common Stock, par value $0.00001 per shareF3,F4 | Jul 29, 2026 | S | 21,217 | $33.4704 | D | 212,204 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
- F2Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
- F3These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.